Silk Fibroin Nanoparticles Prepared by Electrospray As Controlled Release Carriers of Cisplatin
Overview
Biotechnology
Authors
Affiliations
To maintain the anti-tumor activity of cis-dichlorodiamminoplatinum (CDDP) while avoiding its cytotoxicity and negative influence on normal tissue, CDDP-loaded silk fibroin nanoparticles approximately 59 nm in diameter were successfully prepared by electrospray without using organic solvent. CDDP was incorporated into nanoparticles through metal-polymer coordination bond exchange. In vitro release tests showed that the cisplatin in the nanoparticles could be slowly and sustainably released for more than 15 days. In vitro anti-cancer experiments and intracellular Pt content testing indicated that CDDP-loaded silk fibroin nanoparticles were easily internalized by A549 lung cancer cells, transferring CDDP into cancer cells and then triggering their apoptosis. In contrast, the particles were not easily internalized by L929 mouse fibroblast cells and hence showed weaker cell growth inhibition. The CDDP-loaded silk fibroin nanoparticles showed sustained and efficient killing of tumor cells but weaker inhibition of normal cells. In general, this study provides not only a novel method for preparing CDDP-loaded silk fibroin nanoparticles but also a new carrier system for clinical therapeutic drugs against lung cancers and other tumors.
Investigation of Chip Morphology in Elliptical Vibration Micro-Turning of Silk Fibroin.
Wang Z, Luo X, Sun J, Xie W, Piao Y, Jiang Y Micromachines (Basel). 2025; 16(1.
PMID: 39858765 PMC: 11767461. DOI: 10.3390/mi16010110.
Biomaterials in Drug Delivery: Advancements in Cancer and Diverse Therapies-Review.
Drabczyk A, Kudlacik-Kramarczyk S, Jamrozy M, Krzan M Int J Mol Sci. 2024; 25(6).
PMID: 38542103 PMC: 10970185. DOI: 10.3390/ijms25063126.
Su X, Wei L, Xu Z, Qin L, Yang J, Zou Y Biomedicines. 2023; 11(8).
PMID: 37626740 PMC: 10452428. DOI: 10.3390/biomedicines11082244.
Research progress of natural silk fibroin and the application for drug delivery in chemotherapies.
Yu B, Li Y, Lin Y, Zhu Y, Hao T, Wu Y Front Pharmacol. 2023; 13:1071868.
PMID: 36686706 PMC: 9845586. DOI: 10.3389/fphar.2022.1071868.
Sericultural By-Products: The Potential for Alternative Therapy in Cancer Drug Design.
Baci G, Baciu E, Cucu A, Musca A, Giurgiu A, Moise A Molecules. 2023; 28(2).
PMID: 36677907 PMC: 9861160. DOI: 10.3390/molecules28020850.